Brought to you by 
Baxter, Kuros Biosurgery in tissue repair deal; then Kuros regains rights to most candidates
26 Mar 2012
Executive Summary
Baxter's biosurgery business is entering the orthobiologics market. It has licensed exclusive worldwide rights to develop and market a portfolio of bone and soft tissue repair products that will use the company's Tisseel fibrin biomatrix in combination with biologic agents and related binding technology that were invented by Kuros Biosurgery AG.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Medical Devices
- Biomaterials
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Baxter, Kuros Biosurgery in tissue repair deal; then Kuros regains rights to most candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice